Phase II, open - label, single - arm trial of imatinib mesylate in patients with metastatic melanoma harboring c - Kit mutation or amplification. (cancernetwork.com)
The 10 - year survival rate in subjects receiving first - line treatment with imatinib ranged from 64.4 % to 84.4 %. (cancernetwork.com)
[44] Two other phase II clinical trials evaluated the efficacy of imatinib in patients with melanoma — including mucosal melanomas — harboring KIT mutations and / or amplifications, with a subset of cases involving mucosal primaries, and both found a disease control rate of approximately 50 %. (cancernetwork.com)